Free Trial
NASDAQ:IMNM

Immunome (IMNM) Stock Price, News & Analysis

Immunome logo
$9.10 +0.55 (+6.44%)
As of 01:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Immunome Stock (NASDAQ:IMNM)

Key Stats

Today's Range
$8.65
$9.24
50-Day Range
$7.43
$9.79
52-Week Range
$5.15
$16.81
Volume
510,687 shs
Average Volume
892,125 shs
Market Capitalization
$791.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.33
Consensus Rating
Buy

Company Overview

Immunome Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

IMNM MarketRank™: 

Immunome scored higher than 52% of companies evaluated by MarketBeat, and ranked 510th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immunome has only been the subject of 1 research reports in the past 90 days.

  • Read more about Immunome's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunome are expected to decrease in the coming year, from ($2.21) to ($3.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunome is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunome is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunome has a P/B Ratio of 3.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immunome's valuation and earnings.
  • Percentage of Shares Shorted

    16.30% of the float of Immunome has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunome has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunome has recently decreased by 5.44%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Immunome does not currently pay a dividend.

  • Dividend Growth

    Immunome does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.30% of the float of Immunome has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunome has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunome has recently decreased by 5.44%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Immunome has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Immunome this week, compared to 4 articles on an average week.
  • Search Interest

    5 people have searched for IMNM on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Immunome to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunome insiders have bought more of their company's stock than they have sold. Specifically, they have bought $46,900.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 8.60% of the stock of Immunome is held by insiders.

  • Percentage Held by Institutions

    44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunome's insider trading history.
Receive IMNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter.

IMNM Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Immunome initiated with a Buy at Lake Street
See More Headlines

IMNM Stock Analysis - Frequently Asked Questions

Immunome's stock was trading at $10.62 at the beginning of the year. Since then, IMNM stock has decreased by 17.3% and is now trading at $8.7860.

Immunome, Inc. (NASDAQ:IMNM) announced its quarterly earnings results on Monday, May, 12th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.14. The business had revenue of $2.93 million for the quarter, compared to the consensus estimate of $0.46 million. Immunome had a negative net margin of 1,875.21% and a negative trailing twelve-month return on equity of 71.65%.

Immunome (IMNM) raised $30 million in an IPO on Friday, October 2nd 2020. The company issued 2,500,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO.

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Humana (HUM), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
5/12/2025
Today
7/09/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMNM
CIK
1472012
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$30.00
Low Price Target
$20.00
Potential Upside/Downside
+156.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$292.96 million
Net Margins
-1,875.21%
Pretax Margin
-1,875.21%

Debt

Sales & Book Value

Annual Sales
$9.04 million
Price / Cash Flow
N/A
Book Value
$2.27 per share
Price / Book
4.01

Miscellaneous

Free Float
79,529,000
Market Cap
$791.88 million
Optionable
Optionable
Beta
1.92
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:IMNM) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners